Amgen stock holds steady on latest earnings context
Published on 07/21/2026 at 08:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen (US0311621009) stock is anchored by its latest reported numbers, including $33.4 billion in 2025 revenue, $10.2 billion in adjusted net income, and adjusted EPS of $19.35 for the year. The company also reported $8.6 billion in fourth-quarter 2025 revenue, giving investors a dated reference point for the current valuation debate.
Revenue and profit base
Amgen said 2025 revenue rose from $32.6 billion in 2024 to $33.4 billion in 2025, a gain of $0.8 billion. Adjusted net income came in at $10.2 billion in 2025, while adjusted EPS reached $19.35, underscoring the scale of the companys earnings base.
For the fourth quarter of 2025, revenue was $8.6 billion. That quarterly figure matters because it shows how the full-year base was built late in the year, rather than relying on one unusually strong period.
Guidance and margin mix
Amgen guided for 2026 revenue of $34.5 billion to $35.7 billion, which frames the next comparison point for the stock. The range implies year-over-year growth of roughly 3% to 7% against the 2025 revenue level of $33.4 billion.
The same guidance period points to continued earnings power, because the company ended 2025 with adjusted EPS of $19.35 and adjusted net income of $10.2 billion. That combination gives the market a clear profit yardstick for 2026 expectations.
Amgen earnings and guidance snapshot
The latest report gives a clean comparison for revenue, adjusted net income, and adjusted EPS across 2024, 2025, and 2026 guidance.
Biotech peers and market level
In the absence of a fresh company-specific market print, the stock can still be read against its report-driven fundamentals: 2025 revenue of $33.4 billion, adjusted net income of $10.2 billion, and 2026 revenue guidance of $34.5 billion to $35.7 billion. That set of figures gives the stock a measurable path into the next earnings cycle.
For investors comparing large-cap biotech names, the most relevant question is whether revenue growth and profit retention can continue at roughly the implied 3% to 7% top-line pace in 2026. The answer will depend on execution across the companys core drug portfolio and the next quarterly update.
Product mix drives cash flow
Amgen’s portfolio remains the operating engine behind those numbers, with long-running products continuing to support revenue and profitability. The product mix matters because the companys 2025 earnings base of $10.2 billion was not built on a single quarter.
That steadier mix also explains why the 2026 revenue guide is the key number to watch. A business producing $33.4 billion in 2025 revenue and guiding to as much as $35.7 billion in 2026 still has room to re-rate on execution.
Valuation anchor matters
The stock is best framed through the companys latest reported figures rather than through speculation. With 2025 adjusted EPS at $19.35 and revenue at $33.4 billion, Amgen enters the next period with a clear earnings and sales base.
Amgen shares on Nasdaq can be assessed against that backdrop once the next dated price print becomes central again, but the core story remains the same: 2025 revenue, 2025 adjusted net income, and 2026 guidance together define the current setup.
Amgen stock facts
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: NASDAQ: AMGN
- Trading venue: Nasdaq
- Sector / Industry: Health Care / Biotechnology
- Index membership: Nasdaq 100
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
